← All trials
NCT06365047
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Aug 21, 2024
- Primary completion
- Jun 1, 2025
- Completion date
- Jun 1, 2027
- First posted
- Apr 15, 2024
- Last posted
- Aug 19, 2024
- Enrollment
- 70
- Arms / groups
- 2 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Tufts UniversityLead sponsor
- Colgate PalmoliveCollaborator
- Tufts UniversityOfficial
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.